<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00977483</url>
  </required_header>
  <id_info>
    <org_study_id>D-20557-3011</org_study_id>
    <secondary_id>NATHAN1</secondary_id>
    <secondary_id>D-20557/9353000001</secondary_id>
    <nct_id>NCT00977483</nct_id>
  </id_info>
  <brief_title>Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2)</brief_title>
  <acronym>NATHAN1</acronym>
  <official_title>Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2) NATHAN1 A Randomized, Placebo-controlled, Double-blind Multi-centre Trial With 2 Parallel Groups</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MEDA Pharma GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinquest, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ergomed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MEDA Pharma GmbH &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess clinical efficacy and safety of long-term orally administered thioctic acid in the
      treatment of diabetic polyneuropathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stage 1 or 2a diabetic (poly)neuropathy (DNP) (Appendix 3) in patients with diabetes mellitus
      (type I or II); neuropathy impairment score of the lower limbs, enlarged by 7 objective items
      (NISLL+7) ≥ 97.5 percentile (corresponding to 4.43 score points); total symptoms score of the
      feet (TSSfeet) ≤ 5.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1998</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary efficacy variable: Absolute change in the neuropathy impairment score lower limbs enlarged by 7 objective items (NISLL+7) between baseline (mean of Visit 0.3 and 0.4 or last available value before randomisation, respectively) and endpoint</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>NIS, NSC, TSS, LLF, QST, VDT, CDT and HP, QAE by means of the HRDB, amplitude CMAP, DL and MNCV on peroneal and tibial nerves, amplitude SNAP and latency on sural nerve, foot inspection, efficacy.</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">460</enrollment>
  <condition>Diabetic Polyneuropathy</condition>
  <arm_group>
    <arm_group_label>Drug: Thioctic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600mg tablet Thioctic Acid (alpha-lipoic acid) once daily throughout the trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 tablet once daily throughout the trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thioctic Acid</intervention_name>
    <description>600mg tablet once daily 4 years double-blind treatment period</description>
    <arm_group_label>Drug: Thioctic Acid</arm_group_label>
    <other_name>alpha-lipocic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet once daily 4 years double-blind treatment period</description>
    <arm_group_label>Drug: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Informed Consent. Patients must have willingness and complete competence to
             cooperate and language barriers must not preclude adequate understanding

          2. Diabetes mellitus (Type I or II), as defined by the American Diabetes Association
             1997, lasting &gt; 1 year

          3. Males or females 18 to 64 years (older patients are excluded because of age-related
             changes in reflexes, quantitative sensory testing endpoints, and nerve conduction
             endpoints)

          4. Patient must have a symmetric sensory-motor peripheral polyneuropathy attributable to
             diabetes mellitus following a thorough evaluation for other causes of neuropathy
             determined by performing complete medical and neurological examinations including
             physical and neurological history, history of medications, history of exposure to
             other toxins, and laboratory studies

          5. Severity of diabetic polyneuropathy must be Stage 1 or 2a

          6. Insulin regimen, weight, diet, and activity level must be relatively stable in the
             opinion of the investigator (for example, HbA1C must not vary by more than ± 2 Vol.%
             within 6 months preceding the study i.e. if the index measure = 10% the range would be
             8-12%)

          7. NIS[LL]+7 tests ≥ 97.5 percentiles (corresponding to 4.43 transformed score points)

          8. NIS[LL] ≥ 2 points (NIS[LL] is based on questions 17-24, 28, 29, 34, 35, and 37 of the
             NIS)

          9. One of the following:

               -  an abnormality of nerve conduction attributes in two separate nerves, i.e. ≥99th
                  percentile for DL or ≤1st percentile for NCV or amplitude or

               -  an abnormality of HRDB, i.e. ≤ 1st percentile

         10. TSS (feet) ≤5

         11. Females must either be surgically sterilised (tubal ligation, bilateral oophorectomy,
             or hysterectomy) or at least 1 year postmenopausal or practicing an acceptable method
             of contraception, including oral contraceptives with a stable regimen for at least two
             months, depo-medroxyprogesterone, a barrier method alone (diaphragm, condoms, or
             contraceptive sponge with spermicidals), or an IUD that has been in place for at least
             two months

        Exclusion Criteria:

          1. Patients with proximal asymmetric neuropathy, cranial neuropathies, truncal
             radiculopathy, pan dysautonomia, diabetic plexopathies, or acute or active
             mononeuropathies (including cranial neuropathies, post-herpetic neuralgias, etc.), the
             presence of which might obscure accurate assessment of severity of the diabetic
             polyneuropathy under assessment, with the exception of carpal tunnel syndrome (CTS) or
             tardy ulnar neuropathy (TUN) or both

          2. Neuropathy of any cause other than diabetes mellitus which might interfere with the
             assessment of the severity of dPNP Other neurologic diseases that may produce
             weakness, sensory loss, or autonomic symptoms or test abnormality which might
             interfere with the assessment of the severity of dPNP Myopathy of any cause which
             might interfere with the assessment of the severity of dPNP

          3. Peripheral vascular disease severe enough to cause intermittent claudication or
             ischemic ulcers or limb ischemia

          4. Patients with a history of ophthalmological findings suggesting a high risk for visual
             loss i.e., significant maculopathy or proliferative retinopathy

          5. Psychiatric, psychological, or behavioural symptoms that would interfere with the
             patient's ability to participate in the trial

          6. Patients with any active neoplastic disease except basal cell carcinoma

          7. Patients with atrial fibrillation unless controlled and stabilised by medication
             (changed to this criterion by Amendment 1)

          8. Patients with clinically significant cardiac, pulmonary, gastrointestinal,
             hematologic, or endocrine disease (other than diabetes) that may confound
             interpretation of the study results or prevent the patient from completing the study

          9. Patients who have had organ transplants of any kind

         10. Patients with significant hepatic or renal disease (ASAT or ALAT &gt;2 times normal,
             serum creatinine &gt;1.8 mg/dL (&gt;159 µmol/l) for males or &gt;1.6 mg/dL (&gt;141 µmol/l) for
             females)

         11. Patients with a recent history (within last 12 months) of drug or alcohol abuse

         12. Use of any investigational drug within the last 6 months

         13. History of severe or anaphylactic reaction to multiple drugs, sulfur products, or
             biologic products (changed to this criterion by Amendment 1)

         14. Ketoacidosis or hypoglycaemia within last 3 months resulting in hospital admission

         15. Antioxidant therapy (vitamins E &gt; 400IU, C &gt; 200mg, and beta-Carotene &gt; 30mg) or
             pentoxyphylline within last 1 month before start of trial

         16. Use of evening primrose oil or any other gamma-linolenic acid containing substance
             within the last 3 months

         17. Use of thioctic acid &gt; 50mg/day within last 3 months

         18. History of use of medications or vitamins known to cause peripheral neuropathy
             including but not limited to use of phenytoin or carbamazepine over 15 or more years,
             or use of pyridoxine &gt; 100mg/d within the past 12 months

         19. Bilateral sural nerve biopsies

         20. Existing foot ulcers

         21. Pregnant or lactating females

         22. Continued use of medications listed in protocol 6.3.3 (first paragraph)

         23. Medication non-compliance (deviation of more than ±10% of dosages to be taken (1
             tablet/day))
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter James Dyck</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic, Dept. of Neurology, 200 First Street Southwest, Rochester, MN 55905, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>´Diabetes Care Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Building</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Neuromuscular Research Program</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48019-0205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Partners Riverside Neurology Clinic</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454-1478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri Dept. of Neurology</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creighton University Diabetes Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovelace Scientific Resources, Inc.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ney York Hospital Cornell Med Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Carolina University, School of Medicine</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Diabetes &amp; Endocrine Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas South Western Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75325-8858</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes &amp; Glandular Disease Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3894</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leonard R. Strelitz Diabetes Institutes</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic for Diabetes, Endocrinology and Metabolic</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic of Internal Medicine</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Jean Verdler</name>
      <address>
        <city>Bondy Cedex</city>
        <zip>93143</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinic University</name>
      <address>
        <city>Napoli</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Geriatrico Diabetological Service</name>
      <address>
        <city>Padova</city>
        <zip>35137</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosptal of Parma Department of Medicine</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Utrecht Department of Internal Medicine</name>
      <address>
        <city>Utrecht</city>
        <zip>3584</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar Department Neurophysiology</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico y Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U.S. General Hospital</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15705</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic</name>
      <address>
        <city>Malmö</city>
        <zip>20602</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary Department of Medicine</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2009</study_first_submitted>
  <study_first_submitted_qc>September 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2009</study_first_posted>
  <last_update_submitted>November 29, 2016</last_update_submitted>
  <last_update_submitted_qc>November 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2016</last_update_posted>
  <responsible_party>
    <name_title>Dr. Joachim Maus</name_title>
    <organization>MEDA Pharma GmbH &amp; Co. KG</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thioctic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

